Citigroup
BDTX icon

Citigroup’s Black Diamond Therapeutics BDTX Stock Holding History

Citigroup’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.39K Sell
1,592
-22,442
-93% -$53.4K ﹤0.01% 5346
2025
Q4 		$58.4K Buy
24,034
+23,123
+2,538% +$81.9K ﹤0.01% 4518
2025
Q3 		$3.45K Sell
911
-30,903
-97% -$90.4K ﹤0.01% 5343
2025
Q2 		$78.9K Buy
31,814
+1,848
+6% +$3.56K ﹤0.01% 4529
2025
Q1 		$46.4K Sell
29,966
-1,503
-5% -$3.15K ﹤0.01% 4883
2024
Q4 		$67.3K Buy
31,469
+2,664
+9% +$7.63K ﹤0.01% 4996
2024
Q3 		$125K Buy
28,805
+20,642
+253% +$112K ﹤0.01% 4653
2024
Q2 		$38K Sell
8,163
-104,288
-93% -$560K ﹤0.01% 4736
2024
Q1 		$570K Buy
112,451
+58,327
+108% +$235K ﹤0.01% 3473
2023
Q4 		$152K Sell
54,124
-7,224
-12% -$16.9K ﹤0.01% 4043
2023
Q3 		$176K Buy
+61,348
New +$226K ﹤0.01% 3718
2023
Q1 		– Sell
-135
Closed -$243 – 5504
2022
Q4 		$243 Sell
135
-438
-76% -$789 ﹤0.01% 5579
2022
Q3 		$1K Sell
573
-481
-46% -$1.48K ﹤0.01% 5604
2022
Q2 		$3K Sell
1,054
-908
-46% -$2.11K ﹤0.01% 5762
2022
Q1 		$5K Sell
1,962
-4,934
-72% -$18K ﹤0.01% 5796
2021
Q4 		$37K Sell
6,896
-42,002
-86% -$293K ﹤0.01% 5200
2021
Q3 		$414K Sell
48,898
-7,302
-13% -$72.1K ﹤0.01% 3740
2021
Q2 		$685K Sell
56,200
-71,691
-56% -$1.42M ﹤0.01% 3482
2021
Q1 		$3.1M Buy
127,891
+120,421
+1,612% +$3.25M ﹤0.01% 2177
2020
Q4 		$239K Buy
7,470
+4,614
+162% +$152K ﹤0.01% 4859
2020
Q3 		$86K Sell
2,856
-1,133
-28% -$34.5K ﹤0.01% 5227
2020
Q2 		$169K Buy
3,989
+452
+13% +$16.6K ﹤0.01% 5151
2020
Q1 		$88K Buy
+3,537
New +$108K ﹤0.01% 5447

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citigroup's BDTX Position: Q1 2026 in Review

Citigroup reduced its Black Diamond Therapeutics (BDTX) stake by 93% in Q1 2026, selling an estimated $53.4K and leaving 1,592 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #5346.

Citigroup first reported a position in BDTX in Q1 2020 and has held it in 23 quarters since. The position peaked at $3.1M in Q1 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Citigroup held 1,592 shares of Black Diamond Therapeutics worth $3.39K as of Q1 2026.
  • Citigroup sold 22,442 Black Diamond Therapeutics shares in Q1 2026, an estimated $53.4K.
  • Black Diamond Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5346 holding.
  • Citigroup first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Citigroup's Black Diamond Therapeutics position peaked at $3.1M in Q1 2021.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.